Get the Stockscreener App
42.55
0.45%
0.19
After Hours:
42.55
Enliven Therapeutics Inc stock is traded at $42.55, with a volume of 3.45M.
It is up +0.45% in the last 24 hours and up +2.93% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$42.36
Open:
$42.51
24h Volume:
3.45M
Relative Volume:
2.69
Market Cap:
$2.59B
Revenue:
-
Net Income/Loss:
$-98.78M
P/E Ratio:
-25.57
EPS:
-1.6638
Net Cash Flow:
$-65.60M
1W Performance:
+17.83%
1M Performance:
+2.93%
6M Performance:
+151.63%
1Y Performance:
+84.28%
1-Day Range:
$40.95
$44.02
1-Week Range:
$35.71
$47.36
52-Week Range:
$14.79
$48.53
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
42.55 | 2.58B | 0 | -98.78M | -65.60M | -1.6638 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
[144] Enliven Therapeutics, Inc. SEC Filing - Stock Titan
What Does Enliven Therapeutics’ Rule 144 Filing Mean For Investors? - Kalkine Media
Enliven Therapeutics closes $460M public offering - Investing.com UK
Enliven Therapeutics Closes Upsized $460 Million Public Offering - marketscreener.com
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares - PR Newswire
Responsive Playbooks and the ELVN Inflection - Stock Traders Daily
Enliven Therapeutics reports positive phase 1 CML data and FDA alignment for phase 3 trial (ELVN) - MSN
Enliven Therapeutics Prices $400 Million Public Offering - Moomoo
TD Cowen Maintains Enliven Therapeutics(ELVN.US) With Buy Rating - Moomoo
Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial - Insider Monkey
5 Stocks That Absolutely Exploded Higher - Insider Monkey
Why Is Enliven Therapeutics Stock (ELVN) Up Today? - TipRanks
ELVN Stock Jumps As FDA-Cleared Path Fuels Phase 3 Push - timothysykes.com
Enliven Therapeutics Prices ~$376 Million Equity Offering; Jefferies, Goldman, Morgan Stanley Lead - TradingView
Enliven Therapeutics (Nasdaq: ELVN) plans $400M stock and warrant sale - Stock Titan
Enliven Therapeutics (NASDAQ: ELVN) raises $376M via 8.93M-share offering - Stock Titan
Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY) - The Globe and Mail
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development - Yahoo Finance
Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise - StocksToTrade
Enliven (ELVN) Sees Significant Price Increase - GuruFocus
ELVN Stock Jumps As FDA Clears Path For Phase 3 ENABLE Trial - StocksToTrade
Enliven Therapeutics Inc. (NASDAQ: ELVN) Share Price, ELVN Stock News, ELVN Share Price & Updates - Kalkine
Enliven Therapeutics (ELVN) Stock Surges On FDA, Trial Wins - timothysykes.com
Enliven Therapeutics prices upsized $400M public offering of common stock and pre-funded warrants - MSN
Key facts: Enliven posts ELVN-001 Phase 1 data; files $250M offering - TradingView
Enliven Therapeutics, Inc. (ELVN) Discusses Updated Phase 1 ENABLE Trial Data for ELVN-001 in Previously Treated Chronic Myeloid LeukemiaSlideshow (NASDAQ:ELVN) 2026-06-12 - Seeking Alpha
Enliven Therapeutics prices $400M public offering at $37.50 - Investing.com UK
Enliven Therapeutics prices $400M public offering at $37.50 By Investing.com - Investing.com Canada
Enliven Therapeutics Expects Offering to Close on or About June 15 >ELVN - Moomoo
Biotech Enliven prices ~$400 million stock and warrant sale - Stock Titan
Enliven Therapeutics Prices 8.9 Million Shares At $37.50 Per Share - TradingView
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
Enliven Therapeutics launches $250M stock offering - Investing.com UK
Enliven Therapeutics (ELVN) offers $250M stock with pre-funded warrants - Stock Titan
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid - BioWorld News
Enliven Therapeutics launches $250M public stock offering - MSN
Enliven Therapeutics launches $250M stock offering By Investing.com - Investing.com Australia
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PR Newswire
ELVN Stock Pops As Wall Street Targets Phase 3 Catalyst - StocksToTrade
ELVN Stock Jumps As Analysts Hike Price Targets - StocksToTrade
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings - Benzinga
ELVN Stock Pops As Analysts Hike Biotech Price Targets - timothysykes.com
Enliven reports phase 1 trial data for CML drug candidate - Investing.com UK
ELVN: ELVN-001 shows strong efficacy and safety in CML, advancing to pivotal Phase 3 trials - TradingView
Enliven Therapeutics Reports Positive Phase 1 CML Data and FDA Alignment for Phase 3 Trial (ELVN) - Yahoo Finance
Why is Enliven Therapeutics stock surging today? By Investing.com - Investing.com Canada
Biggest stock movers: DAN, ORCL, HUMA, and more - Seeking Alpha
Enliven Shares Climb on Positive Leukemia Drug Trial Data - marketscreener.com
Enliven Therapeutics, DXC Technology, Humacyte - TradingView
Enliven Therapeutics stock surges on positive trial data By Investing.com - Investing.com South Africa
Enliven posts new trial data for leukemia drug (ELVN:NASDAQ) - Seeking Alpha
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
1.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):